SLC16A1 and breast cancer: Breast was chosen because (i) human breast cancers generally have high MCT1 expression [31,42], (ii) AZD3965 was previously documented to exert strong anticancer effects in preclinical breast cancer models [31], (iii) AZD3965 has favorable pharmacokinetics in breast cancer-bearing mice with an intratumoral accumulation of ~1 μmol/L 12 h after the oral administration of 100 mg/Kg [33] and (iv) for the existence of a naturally immortalized nonmalignant human breast epithelial cell line (MCF10A) [43].